In the past two weeks, weight loss drug leaders such as Novo Nordisk and Eli Lilly saw significant drops in their stock prices due to various factors. Eli Lilly reported strong Q2 earnings, but disappointing clinical trial data for their new weight loss drug, orforglipron, led to a massive sell-off.

The Phase 3 ATTAIN-1 results for orforglipron showed a 11.5% weight loss compared to a placebo at 72 weeks, falling below expectations. This data raised concerns about Lilly’s scientific dominance in the weight loss drug market and potential competition from other GLP-1 makers.

Despite the setback, Lilly’s sell-off may be overdone, presenting a buy-the-dip opportunity for investors. The company aims to reach new patient groups with orforglipron, although competition from Novo Nordisk’s oral GLP-1 could pose a challenge. There is still potential for Lilly to tap into the underpenetrated weight loss drug market.

Overall, Lilly’s stock fall highlights the volatility in the pharmaceutical industry, but with a long growth runway in weight loss drugs, investors may find value in buying the dip. Analysts suggest a potential 11% upside for Lilly’s stock, emphasizing the opportunity for growth in the future.

Read more at Nasdaq: Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?